Response to: Tocilizumab,neuromyelitis optica (NMO),and multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Araki

Aranami

Matsuoka

. et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013; 23: 827–831.

Araki

Matsuoka

Miyamoto

. et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology 2014; 82: 1302–1306.

Ayzenberg

Kleiter

Schroder

. et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013; 70: 394–397.